Cognition Therapeutics Inc Sustainability Reports
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. Its lead product candidate, zervimesine (CT1812), is designed to treat diseases such as Alzheimer's disease and Dementia with Lewy bodies.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG001V0GFB9
2 reports from 2021 to 2024
